Clinical Trials Logo

Clinical Trial Summary

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of RSVpreF in the prevention of moderate to severe LRTI-RSV in adults.


Clinical Trial Description

This is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study to assess the safety, immunogenicity, and efficacy of RSVpreF or placebo (1:1 randomization) in adults. This will be a global study that will span multiple RSV seasons. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05035212
Study type Interventional
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email [email protected]
Status Recruiting
Phase Phase 3
Start date August 31, 2021
Completion date June 19, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03756753 - The RAPID Trial: Assessing Point-of-care Influenza and Other Respiratory Virus Diagnostics N/A